Relapsed or Refractory Lymphoma

Oncology
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

H
HutchmedChina - Hong Kong
3 programs
3
HMPL-523Phase 11 trial
HMPL-523Phase 11 trial
Itraconazole 200 mgPhase 11 trial
Active Trials
NCT05720767Completed28Est. Feb 2023
NCT05571787Completed26Est. Sep 2022
NCT05602597Completed59Est. Aug 2022

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
HutchmedHMPL-523
HutchmedHMPL-523
HutchmedItraconazole 200 mg

Clinical Trials (3)

Total enrollment: 113 patients across 3 trials

HMPL-523 CYP3A/P-gp Inhibitor and CYP Inducer Study

Start: Nov 2022Est. completion: Feb 202328 patients
Phase 1Completed

HMPL-523 Food Effect and Proton Pump Inhibitor Study

Start: Jul 2022Est. completion: Sep 202226 patients
Phase 1Completed
NCT05602597HutchmedItraconazole 200 mg

HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI

Start: Jun 2022Est. completion: Aug 202259 patients
Phase 1Completed

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space